1. Prognostic Value of Endocan in Prostate Cancer: Clinicopathologic Association between Serum Endocan Levels and Biochemical Recurrence after Radical Prostatectomy
   Burak Arslan et al, 2017, Tumori Journal CrossRef
2. Immunohistochemical investigation of cytokine expression levels as biomarkers in transrectal ultrasound‑guided needle biopsy specimens of prostate adenocarcinoma
   Jagtar Singh et al, 2021, Molecular and Clinical Oncology CrossRef
3. IL-6 and IL-8 cytokines are associated with elevated prostate-specific antigen levels among patients with adenocarcinoma of the prostate at the Uganda Cancer Institute
   Paul Katongole et al, 2022, Future Oncology CrossRef
4. Differential expression of E-cadherin and P-cadherin in pT3 prostate cancer: correlation with clinical and pathological features
   Catarina Ferreira et al, 2018, Virchows Archiv CrossRef
5. An insight into the complex roles of metallothioneins in malignant diseases with emphasis on (sub)isoforms/isoforms and epigenetics phenomena
   Sona Krizkova et al, 2018, Pharmacology & Therapeutics CrossRef
6. Identification of a Robust Five-Gene Risk Model in Prostate Cancer: A Robust Likelihood-Based Survival Analysis
   Yutao Wang et al, 2020, International Journal of Genomics CrossRef
7. Metallothionein 2A (MT2A) controls cell proliferation and liver metastasis by controlling the MST1/LATS2/YAP1 signaling pathway in colorectal cancer
   Xi Liu et al, 2022, Cancer Cell International CrossRef